Navigation Links
Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
Date:12/7/2012

looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2011, and Form 10-Q for the quarter ended September 30, 2012, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.For More Information, Contact:James E. Fickenscher / CFO

William Q. Sargent, Jr. / V.P., IR
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
2. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
4. Auxilium Announces Appointments to Enhance Leadership Team
5. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
6. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
8. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
9. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
10. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Vermillion, Inc. (Nasdaq:   VRML), a ... today that investors including Oracle Investment Management, ... several Vermillion directors have agreed to purchase approximately ... stock and warrants to purchase unregistered shares of ... Under the terms of the private ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/24/2014)... , Dec. 23, 2014  NeuroLifeSciences announced today ... in children with attention deficit/hyperactivity disorder published in ... The paper, titled "Pilot Phase 2 ... ( Konofal et al, Drug Des Devel ... shows that mazindol might be an effective, well-tolerated, ...
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 16 Regado Biosciences, a privately held company leading ... announced that David J. Mazzo, PhD, President and CEO, ... Conference.  Dr. Mazzo,s presentation will be given at the ... September 22, 2010 at 8:00 a.m. EDT in Ballroom ...
... DENVER, Sept. 16 BioSpace and BioMed ... BioMed Central Career Network today, ... professionals seeking quality recruitment, job opportunities and ... ) (Logo: http://photos.prnewswire.com/prnh/20040907/CLTU006LOGO ) ...
... (NYSE: CRY ), an implantable biological medical device ... participate in the UBS Global Life Sciences Conference at The ... Ashley Lee, executive vice president, chief operating officer and chief ... on Tuesday, September 21, 2010 at 3:30 p.m., Eastern Time. ...
Cached Biology Technology:Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 2Regado Biosciences to Present at the UBS Global Life Sciences Conference on September 22, 2010 in New York City 3BioSpace and BioMed Central Create Global Career Community 2CryoLife to Present at UBS Global Life Sciences Conference 2
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ... Market Monitor: North America Perimeter Security Systems Market" ... http://photos.prnewswire.com/prnh/20130307/600769 The North American perimeter security ... 3.6% from 2014 to 2019. Although the U.S. market ... Canada is expected to grow at a ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
Breaking Biology News(10 mins):Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... (NTU) and Temasek Foundation are working together to ... People,s Republic of China which are prone to ... seismic-resistant construction technologies, the programme aims to promote ... enhance the skills of those involved in China ...
... -- Researchers at Burnham Institute for Medical Research ... University of Maryland have demonstrated that an enzyme ... targeted to kill dangerous pathogens. In addition, investigators ... and suppress the growth of pathogenic bacteria. These ...
... University has succeeded in extracting long DNA fragments from ... Linnaeus, apprentice Adam Afzelius. It is hoped that the ... light on whether plants growing today at Linnaeus, Hammarby ... himself. A large number of plants of uncertain ...
Cached Biology News:NTU and Temasek Foundation transfer technology knowhow to China's quake-prone regions 2NTU and Temasek Foundation transfer technology knowhow to China's quake-prone regions 3The path to new antibiotics 2
... General description: Designed for use with ... CLS number is a new product number, ... If showing no availability yet, please order ... contact customer service for assistance. Comp Dim: ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... Stem Cell Identification Kit. ... a substrate for the ... that is highly expressed ... cells, making ALDH an ...
... LED produces output at 470 nm; includes interface ... S2000 or installed into rack or desktop boxes ... Source is an LED that produces either pulsed ... blue region -- for fluorescence measurements. The source ...
Biology Products: